Cargando…
Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents
Recent advances in targeted therapy with monoclonal antibodies have significantly improved outcomes for people with cancer, sometimes allowing patients to avoid ovotoxic agents altogether. The current understanding is that monoclonal antibody cancer therapies that are not targeted to ovarian antigen...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209836/ https://www.ncbi.nlm.nih.gov/pubmed/35727422 http://dx.doi.org/10.1007/s10815-022-02548-3 |